Combination Immunotherapy Targeting Sarcomas
Trial statusRecruiting
Trial phasePhase 1, Phase 2
Trial typeInterventional
Biological sexAll
Age1-75
SponsorShenzhen Geno-Immune Medical Institute
About this trial
The aim of this clinical trial is to assess the feasibility, safety and efficacy of a combination low dose chemotherapy and immunotherapy in patients who have sarcoma that is relapsed or late staged. Another goal of the study is to assess the safety and efficacy of the therapy that combines multiple CAR T cells followed by sarcoma vaccines.
Eligibility criteria
Qualifiers
Stage Ⅲ，Ⅳ sarcoma patients or recurrent sarcoma patients;
Age: ≥ 6 months and ≤80 years of age at the time of enrollment;
At least 2 weeks since the last standard chemotherapy or radiotherapy and immunosuppressive therapy such as steroid hormone before enrollment;
Side effects of chemotherapy have been well managed;
Disqualifiers
The disease is progressing rapidly;
The patient is receiving therapy of other new drugs and under evaluation;
Evidence of tumor potentially causing airway obstruction;
Epilepsy history or other CNS diseases;
Trial design
Treatments tested in this trial
- Multiple sarcoma-specific CAR-T cells and sarcoma vaccines
Treatment groups
20 Participants
are divided into 1 treatment groupLocations
1Shenzhen Geno-Immune Medical Institute518000, ShenzhenGuangdong, China
Sponsors and collaborators
Shenzhen Geno-Immune Medical Institute
Lead sponsor
Source ClinicalTrials.gov